SynX and Roche join forces in emerging CHF (congestive heart failure) sector
This article was originally published in Clinica
Executive Summary
In a move that it claims allows it to "align with an industry leader", SynX Pharma has acquired from Roche Diagnostics rights to a congestive heart failure (CHF) marker for point-of-care testing. Simultaneously SynX has licensed rights to Roche concerning its own diagnostic for CHF.